Yan Bo Zeng

All Publications

• Cost-Effectiveness of Nirsevimab and Maternal RSVpreF Immunization Strategies in Low-Risk Infants. Pediatrics Tsung, S., Zeng, Y. B., Shah, K., Asch, S. M., Salomon, J. A., Owens, D. K., Chen, K. 2026

  Abstract

  In 2023, the Advisory Committee on Immunization Practices (ACIP) recommended both nirsevimab for infants aged less than 8 months and RSVpreF vaccine for pregnant patients at 32 to 36 weeks' gestation to prevent respiratory syncytial virus (RSV)-associated lower respiratory tract infections in infants. We compared the cost-effectiveness of the ACIP-recommended mixed nirsevimab and RSVpreF strategy vs a nirsevimab-only strategy for healthy, low-risk infants in the United States.A decision tree with nested Markov models compared 3 immunization strategies for healthy low-risk infants: no immunization, a mixed strategy of RSVpreF and nirsevimab per ACIP guidelines, and nirsevimab only for all infants. We estimated health and societal outcomes using quality-adjusted life years (QALYs) and costs from a health care sector perspective (ie, direct medical costs) and a societal perspective (ie, factors like caregiver productivity loss). We assessed cost-effectiveness using incremental cost-effectiveness ratios (ICERs) and a willingness-to-pay threshold of $150 000/QALY to benchmark cost-effectiveness and conducted sensitivity analyses.From the health care sector perspective, neither the mixed strategy nor the nirsevimab-only strategy was cost-effective compared with no immunization, according to the $150 000/QALY threshold. From the societal perspective, the mixed strategy was cost-effective compared with no immunization ($117 848/QALY). Due to higher product costs, nirsevimab alone was not cost-effective compared with the mixed strategy ($347 821/QALY). However, if RSVpreF was not an option, the nirsevimab-only strategy would be cost-effective compared with no immunization ($134 391/QALY). Results were sensitive to assumptions about product costs and efficacy.Pediatricians and obstetricians should jointly recommend RSV immunizations, as the ACIP-recommended mixed RSVpreF and nirsevimab strategy is a societally cost-effective method to protect infants.

  View details for DOI 10.1542/peds.2025-071558

  View details for PubMedID 41713490

• Distance-stratified sociodemographic differences in telemedicine use in surgical oncology clinics at an academic medical center. NPJ digital medicine Parameswaran, V., Tsung, S., Zeng, Y. B., Miller, M., Pritchett, J., Demaerschalk, B. M., Rosengaus, L., Sharp, C., Lee, B., Shah, S. 2026

  Abstract

  We examined telemedicine use across 38,883 surgical oncology visits (2021-2023) at a Northern California cancer center. At ≥20 miles from clinics, Hispanic (OR = 0.76, 95% CI [0.68,0.85]), Asian/Pacific Islander (OR = 0.75, 95% CI [0.66,0.84]), interpreter-needing (OR = 0.67, 95% CI [0.59,0.77]), and Medicaid patients (OR = 0.85, 95% CI [0.76,0.96]) had lower telemedicine use, while low-income patients showed higher utilization (OR = 1.67, 95% CI [1.46,1.91]). At <20 miles, no differences were observed for Hispanic, interpreter-needing, Medicaid, or low-income patients, but Asian/Pacific Islanders showed higher use (OR = 1.16, 95% CI [1.04-1.30]). Geographic distance modifies telemedicine access patterns.

  View details for DOI 10.1038/s41746-026-02411-0

  View details for PubMedID 41691087

• Telemedicine Trends in Ambulatory Surgical Oncology: A Five-Year Analysis of Visit Volume and Utilization at a High-Volume Academic Center. Annals of surgical oncology Parameswaran, V., Miller, M., Pritchett, J., Demaerschalk, B., Hu, Y., Tsung, S., Zeng, Y. B., Rosengaus, L., Sharp, C., Lee, B., Shah, S. 2025

  Abstract

  Telemedicine is now a sustained modality of ambulatory surgical oncology care, yet its association with workforce utilization, patient volume, and visit type at high-volume academic centers remains understudied. Characterizing these patterns is essential for guiding clinical operations and long-term integration of telemedicine into surgical oncology practice.We conducted a retrospective cohort study across nine oncology subspecialties at Stanford Medicine's ambulatory surgical oncology clinics from January 2019 to December 2023 to compare yearly visit volumes and telemedicine use. The study included a total of 231,746 visits, including 50,667 new and 181,079 return visits. We measured overall visit volumes, telemedicine utilization, and their association with increase in unique patients served, including both new and return visits.In 2023, visit volumes increased by 44% (46,726 to 67,259), and the clinician workforce grew by 16.8% (107 to 125) compared with 2019. The number of unique patients served rose by 39% (20,620 to 28,711), while visits per patient remained stable (2.3 ± 2.1 to 2.3 ± 2.2). Telemedicine use increased from 0.5% (244/46,726) to 37% (24,906/67,259), correlating with serving more patients per year (r = 0.776, p = 0.030) and return visits (r = 0.796, p = 0.010), but not new visits (r = 0.432, p = 0.245).At this academic medical center, telemedicine use is associated with an expansion of the clinician workforce, an increase in patient volume, and more return visits rather than new visits, without contributing to overall higher healthcare utilization. This suggests that telemedicine can deliver a significant proportion of ambulatory surgical oncological visits while preserving access to care and operational efficiency.

  View details for DOI 10.1245/s10434-025-17592-3

  View details for PubMedID 40498347

  View details for PubMedCentralID 9331038

• Impact of telemedicine on access to care in surgical oncology clinics: Distance and time to visit analysis for new patients at a multispecialty cancer center. Parameswaran, V., Tsung, S., Zeng, Y., Miller, M., Pritchett, J. C., Demaerschalk, B., Rosengaus, L., Sharp, C., Lee, B., Shah, S. LIPPINCOTT WILLIAMS & WILKINS. 2025: e23345

  View details for DOI 10.1200/JCO.2025.43.16_suppl.e23345

  View details for Web of Science ID 001690328500004